<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Retrovirology</journal-id><journal-title>Retrovirology</journal-title><issn pub-type="epub">1742-4690</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19604405</article-id><article-id pub-id-type="pmc">2717047</article-id><article-id pub-id-type="publisher-id">1742-4690-6-67</article-id><article-id pub-id-type="doi">10.1186/1742-4690-6-67</article-id><article-categories><subj-group subj-group-type="heading"><subject>Short Report</subject></subj-group></article-categories><title-group><article-title>Ethnic differences in the adaptation rate of HIV gp120 from a vaccine trial</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>P&#x000e9;rez-Losada</surname><given-names>Marcos</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>mlosada@genoma-llc.com</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Posada</surname><given-names>David</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>dposada@genoma-llc.com</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Arenas</surname><given-names>Miguel</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>miguelab@uvigo.es</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Jobes</surname><given-names>David V</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>djobes@gmail.com</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Sinangil</surname><given-names>Faruk</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>fsinagil@gsid.org</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Berman</surname><given-names>Phillip W</given-names></name><xref ref-type="aff" rid="I5">5</xref><email>pwb@soe.ucs.edu</email></contrib><contrib id="A7" contrib-type="author"><name><surname>Crandall</surname><given-names>Keith A</given-names></name><xref ref-type="aff" rid="I6">6</xref><email>kcrandall@genoma-llc.com</email></contrib></contrib-group><aff id="I1"><label>1</label>CIBIO, Centro de Investiga&#x000e7;&#x000e3;o em Biodiversidade e Recursos Gen&#x000e9;ticos, Universidade do Porto, Campus Agr&#x000e1;rio de Vair&#x000e3;o, 4485-661 Vair&#x000e3;o, Portugal</aff><aff id="I2"><label>2</label>Departamento de Bioqu&#x000ed;mica, Gen&#x000e9;tica e Inmunolog&#x000ed;a. Universidad de Vigo, 36310 Vigo, Spain</aff><aff id="I3"><label>3</label>Presidio Pharmaceuticals, Inc., San Francisco, CA 94158, USA</aff><aff id="I4"><label>4</label>Global Solutions for Infectious Diseases, South San Francisco, CA 94080, USA</aff><aff id="I5"><label>5</label>Department of Biomolecular Engineering, University of California, Santa Cruz, CA 95064, USA</aff><aff id="I6"><label>6</label>Department of Biology, Brigham Young University, Provo, UT 84602, USA</aff><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>15</day><month>7</month><year>2009</year></pub-date><volume>6</volume><fpage>67</fpage><lpage>67</lpage><ext-link ext-link-type="uri" xlink:href="http://www.retrovirology.com/content/6/1/67"/><history><date date-type="received"><day>3</day><month>5</month><year>2009</year></date><date date-type="accepted"><day>15</day><month>7</month><year>2009</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2009 P&#x000e9;rez-Losada et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2009</copyright-year><copyright-holder>P&#x000e9;rez-Losada et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author>
               P&#x000e9;rez-Losada
               Marcos
               
               mlosada@genoma-llc.com
            </dc:author><dc:title>
            Ethnic differences in the adaptation rate of HIV gp120 from a vaccine trial
         </dc:title><dc:date>2009</dc:date><dcterms:bibliographicCitation>Retrovirology 6(1): 67-. (2009)</dcterms:bibliographicCitation><dc:identifier type="sici">1742-4690(2009)6:1&#x0003c;67&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1742-4690</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><p>Differences in HIV-1 gp120 sequence variation were examined in North American volunteers who became infected during a phase III vaccine trial using the rgp120 vaccine. Molecular adaptation of the virus in vaccine and placebo recipients from different ethnic subgroups was compared by estimating the <italic>d</italic><sub>N</sub>/<italic>d</italic><sub>S </sub>ratios in viruses sampled from each individual using three different methods. ANOVA analyses detected significant differences in <italic>d</italic><sub>N</sub>/<italic>d</italic><sub>S </sub>ratios among races (<italic>P </italic>&#x0003c; 0.02). gp120 sequences from the black individuals showed higher mean <italic>d</italic><sub>N</sub>/<italic>d</italic><sub>S </sub>ratios for all estimators (1.24&#x02013;1.45) than in other races (0.66&#x02013;1.35), and several pairwise comparisons involving blacks remained significant (<italic>P </italic>&#x0003c; 0.05) after correction for multiple tests. In addition, black-placebo individuals showed significantly (<italic>P </italic>&#x0003c; 0.02) higher mean <italic>d</italic><sub>N</sub>/<italic>d</italic><sub>S </sub>ratios (1.3&#x02013;1.66) than placebo individuals from the other races (0.65&#x02013;1.56). These results suggest intrinsic differences among races in immune response and highlight the need for including multiple ethnicities in the design of future HIV-1 vaccine studies and trials.</p></abstract></article-meta></front><body><sec><title>Findings</title><p>More than 33 million people are currently infected with HIV-1, resulting in 2&#x02013;3 million deaths every year. Natural immunity to the virus is virtually nonexistent; hence, the creation of a vaccine to combat this global pandemic is an international public-health priority [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>]. In 2003, the results were released for a phase III HIV-1 vaccine efficacy trial conducted in North America and The Netherlands (VAX004) [<xref ref-type="bibr" rid="B3">3</xref>]. This study tested the efficacy of bivalent vaccines containing recombinant HIV-1 envelope glycoprotein 120 (rgp120) antigens, the major antigen on the surface of the virus [<xref ref-type="bibr" rid="B4">4</xref>]. Overall, the vaccine candidate did not seem to reduce the incidence of HIV-1 infection, but an interesting trend was noted in the analysis of the different self-described ethnic groups [white (non-Hispanic), blacks, Hispanic, Asian, and "others"]. When only the non-white volunteers (17% of the total study population) were considered, the vaccine seemed to confer a slight benefit (<italic>P </italic>= 0.012). After adjustment for multiple tests, this difference was not significant (<italic>P </italic>= 0.13) [<xref ref-type="bibr" rid="B3">3</xref>]. Despite a lack of statistical support, this is not a trivial result. If this trend was to be confirmed, it would imply that non-whites developed protective immunity to HIV-1 or, even more important, that rgp120 immunogens could protect against HIV infection under certain circumstances. Here we explored this possibility further.</p><p>HIV-1 evolution is driven, to a significant extent, by the immune response. If viruses isolated from non-white patients are in fact under a stronger selection pressure either because of genetic differences in the magnitude, specificity, or potency of the natural immune response, or because of differences in factors affecting virus replication, we should expect higher ratios of nonsynonymous (amino acid changing) to synonymous nucleotide substitutions (<italic>d</italic><sub>N</sub>/<italic>d</italic><sub>S</sub>) [<xref ref-type="bibr" rid="B5">5</xref>-<xref ref-type="bibr" rid="B8">8</xref>] than in viral samples isolated from vaccinated and placebo (non-vaccinated) white individuals.</p><p>To test whether levels of selection were significantly different between vaccinated and placebo individuals in different races, we analyzed 3 clones per individual from 345 infected North Americans from the VAX004 study (Table <xref ref-type="table" rid="T1">1</xref>; data available at <ext-link ext-link-type="uri" xlink:href="http://www.gsid.org"/>). Full-length HIV-1 subtype B gp120 sequences were amplified as described in Gilbert et al. [<xref ref-type="bibr" rid="B9">9</xref>]. Since, as expected, viruses isolated from individuals from the same race did not form monophyletic groups [<xref ref-type="bibr" rid="B10">10</xref>], viral samples for each patient were analyzed separately. In each case, individual clones were aligned in MAFFT v5.7 [<xref ref-type="bibr" rid="B11">11</xref>], and <italic>d</italic><sub>N</sub>/<italic>d</italic><sub>S </sub>ratios were estimated using Nei and Gojobori's method [<xref ref-type="bibr" rid="B6">6</xref>] in SNAP [<xref ref-type="bibr" rid="B12">12</xref>], model M0 (one-ratio) in PAML v3.14 [<xref ref-type="bibr" rid="B13">13</xref>], and Fixed Effects Likelihood (FEL) with tree branch correction in HYPHY [<xref ref-type="bibr" rid="B14">14</xref>]. In the latter case, we took recombination into account by first detecting recombination breakpoints with GARD [<xref ref-type="bibr" rid="B15">15</xref>], and then estimating the <italic>d</italic><sub>N</sub>/<italic>d</italic><sub>S </sub>ratios independently for each fragment.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Mean <italic>d</italic><sub>N</sub>/<italic>d</italic><sub>S </sub>estimates across patients in PAML, SNAP and HYPHY. </p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="left">White (291)</td><td align="left">Hispanic (22)</td><td align="left">Black (12)</td><td align="left">Asian (5)</td><td align="left">Other (15)</td></tr></thead><tbody><tr><td align="left">SNAP</td><td align="left">0.709</td><td align="left">0.750</td><td align="left">1.240</td><td align="left">0.818</td><td align="left">0.659</td></tr><tr><td align="left">PAML</td><td align="left">0.839</td><td align="left">0.826</td><td align="left">1.411</td><td align="left">1.346</td><td align="left">0.751</td></tr><tr><td align="left">HYPHY</td><td align="left">0.949</td><td align="left">0.729</td><td align="left">1.453</td><td align="left">0.720</td><td align="left">1.202</td></tr></tbody></table><table-wrap-foot><p>Individuals analyzed are indicated between parentheses.</p></table-wrap-foot></table-wrap><p>Mean <italic>d</italic><sub>N</sub>/<italic>d</italic><sub>S </sub>ratios across races and treatments were compared using ANOVA, linear models (<italic>lm</italic>) and pairwise t-tests. Because treating all non-whites as a single unit is unrealistic considering their own genetic differences [<xref ref-type="bibr" rid="B3">3</xref>], we tested for differences in selection pressure on a race-by-race basis. Multiple significance in the pairwise t-tests was corrected using the Benjamini and Hochberg's procedure [<xref ref-type="bibr" rid="B16">16</xref>].</p><p>The estimates of <italic>d</italic><sub>N</sub>/<italic>d</italic><sub>S </sub>obtained with SNAP, PAML and HYPHY were all significantly correlated among the different estimators used (correlation coefficient &#x0003e; 0.85; <italic>P </italic>&#x0003c; 0.001). Importantly, the mean <italic>d</italic><sub>N</sub>/<italic>d</italic><sub>S </sub>ratios varied across races (Table <xref ref-type="table" rid="T1">1</xref>), and these differences were globally significant (ANOVA;<italic>P </italic>&#x0003c; 0.02) for SNAP and PAML estimates. Blacks (vaccinees and placebo combined) showed higher <italic>d</italic><sub>N</sub>/<italic>d</italic><sub>S </sub>ratios for all the estimators than individuals from other ethnicities (Table <xref ref-type="table" rid="T1">1</xref>). Significant differences (pairwise t-tests; <italic>P </italic>&#x0003c; 0.05) between black and white, Hispanic and "others" viral samples were observed for all the estimators before corrections, but only the comparisons involving SNAP and PAML estimates remained significant after the Benjamini and Hochberg's adjustment (Table <xref ref-type="table" rid="T2">2</xref>). The higher <italic>d</italic><sub>N</sub>/<italic>d</italic><sub>S </sub>ratios observed for blacks suggest that the rate of virus evolution is greater in this group than in other volunteers. Differences in immune response to HIV-1 infection have been pointed out by the rgp120 HIV Vaccine Study Group [<xref ref-type="bibr" rid="B3">3</xref>] as one of the potential factors to explain vaccine efficiency differences between white and non-white volunteers in the VAX004 trial. Ethnic differences in immune response have been also reported for other viruses such as the hepatitis C virus [<xref ref-type="bibr" rid="B17">17</xref>].</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Statistically significant comparisons of <italic>d</italic><sub>N</sub>/<italic>d</italic><sub>S </sub>estimates among races and race-treatments. </p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="left" colspan="2">Race</td><td align="left" colspan="2">Race by treatment</td></tr><tr><td></td><td colspan="2"><hr></hr></td><td colspan="2"><hr></hr></td></tr><tr><td align="left">Method</td><td align="left">ANOVA</td><td align="left">Corrected pairwise t-tests</td><td align="left">ANOVA</td><td align="left"><italic>lm </italic>coefficient</td></tr></thead><tbody><tr><td align="left">SNAP</td><td align="left">(0.011)</td><td align="left">black vs hispanic (0.020)<break/>black vs other (0.013)<break/>black vs white (0.004)</td><td align="left">(0.025)</td><td align="left">black placebo (0.001)</td></tr><tr><td align="left">PAML</td><td align="left">(0.019)</td><td align="left">black vs hispanic (0.047)<break/>black vs other (0.047)<break/>black vs white (0.033)</td><td></td><td align="left">black placebo (0.016)</td></tr><tr><td align="left">HYPHY</td><td></td><td></td><td></td><td align="left">black placebo (0.015)</td></tr></tbody></table><table-wrap-foot><p>Values in parentheses are <italic>P</italic>-values.</p></table-wrap-foot></table-wrap><p>Does the greater virus adaptive variation presumed in black participants reflect genetic differences in the intrinsic (no-preconditioned) immune response to HIV-1, or is it a consequence of the conditioned immune response induced by vaccination with rgp120? Comparison of vaccine and placebo recipients showed different results based on the <italic>d</italic><sub>N</sub>/<italic>d</italic><sub>S </sub>estimators used. No significant differences were observed among vaccinees, but significant differences (ANOVA; <italic>P </italic>= 0.025) in SNAP <italic>d</italic><sub>N</sub>/<italic>d</italic><sub>S </sub>ratios were detected among placebo individuals. Moreover, black-placebo patients showed significantly (<italic>lm </italic>coefficients; <italic>P </italic>&#x0003c; 0.02) higher mean <italic>d</italic><sub>N</sub>/<italic>d</italic><sub>S </sub>ratios (1.3, 1.38 and 1.66, for SNAP, PAML and HYPHY, respectively) than the other races (0.65&#x02013;1.01, 0.84&#x02013;1.14 and 0.73&#x02013;1.56, respectively). These results might indicate that natural differences in the immune response may have increased viral rgp120 adaptation in blacks.</p><p>In North America, blacks correspond to 42% of all newly diagnosed HIV/AIDS cases, while white (non-Hispanic) and Hispanic individuals represent approximately 40% and 17%, respectively [<xref ref-type="bibr" rid="B18">18</xref>]. If more data including both placebo and vaccinated recipients confirm that selection pressure differs between viruses infecting these three races, deciphering the genetic determinants of these differences should become a public-health priority. Indeed, our results highlight the need for selecting a broader representation of volunteers, based on ethnicity, in the design of future HIV-1 vaccine studies and trials [<xref ref-type="bibr" rid="B19">19</xref>].</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>MPL, DP, and KC developed the genetic and statistical strategies implemented in this work. MPL, DP, and MA performed the genetic and statistical analyses. DVJ, FS, and PWB carried out the molecular genetic studies and immunoassays. All authors participated in the design of the study and helped to draft the manuscript. All authors read and approved the final manuscript.</p></sec></body><back><ack><sec><title>Acknowledgements</title><p>This study was supported by a Bill &#x00026; Melinda Gates Foundation grant to Global Solutions for Infectious Diseases. It was also supported by the Spanish Ministry of Science and Education [grant number BIO2007-61411 to DP, FPI fellowship BES-2005-9151 to MA]. We also want to thank the reviewers for their excellent suggestions.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Esparza</surname><given-names>J</given-names></name><name><surname>Bhamarapravati</surname><given-names>N</given-names></name></person-group><article-title>Accelerating the development and future availability of HIV-1 vaccines: why, when, where, and how?</article-title><source>Lancet</source><year>2000</year><volume>355</volume><fpage>2061</fpage><lpage>2066</lpage><pub-id pub-id-type="pmid">10885368</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(00)02360-6</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Spearman</surname><given-names>P</given-names></name></person-group><article-title>HIV vaccine development: lessons from the past and promise for the future</article-title><source>Curr HIV Res</source><year>2003</year><volume>1</volume><fpage>101</fpage><lpage>120</lpage><pub-id pub-id-type="pmid">15043215</pub-id><pub-id pub-id-type="doi">10.2174/1570162033352093</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><collab>rgp120 HIV Vaccine Study Group</collab></person-group><article-title>Placebo controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. rgp120 HIV Vaccine Study Group</article-title><source>J Infect Dis</source><year>2005</year><volume>191</volume><fpage>654</fpage><lpage>665</lpage><pub-id pub-id-type="pmid">15688278</pub-id><pub-id pub-id-type="doi">10.1086/428404</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Eggink</surname><given-names>D</given-names></name><name><surname>Melchers</surname><given-names>M</given-names></name><name><surname>Sanders</surname><given-names>RW</given-names></name></person-group><article-title>Antibodies to HIV-1: aiming at the right target</article-title><source>Trends Microbiol</source><year>2007</year><volume>15</volume><fpage>291</fpage><lpage>294</lpage><pub-id pub-id-type="pmid">17566740</pub-id><pub-id pub-id-type="doi">10.1016/j.tim.2007.05.006</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sharp</surname><given-names>PM</given-names></name></person-group><article-title>In search of molecular Darwinism</article-title><source>Nature</source><year>1997</year><volume>385</volume><fpage>111</fpage><lpage>112</lpage><pub-id pub-id-type="pmid">8990106</pub-id><pub-id pub-id-type="doi">10.1038/385111a0</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nei</surname><given-names>M</given-names></name><name><surname>Gojobori</surname><given-names>T</given-names></name></person-group><article-title>Simple methods for estimating the numbers of synonymous and nonsynonymous nucleotide substitutions</article-title><source>Mol Biol Evol</source><year>1986</year><volume>3</volume><fpage>418</fpage><lpage>426</lpage><pub-id pub-id-type="pmid">3444411</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ross</surname><given-names>HA</given-names></name><name><surname>Rodrigo</surname><given-names>AG</given-names></name></person-group><article-title>Immune-mediated positive selection drives human immunodeficiency virus type 1 molecular variation and predicts disease duration</article-title><source>J Virol</source><year>2002</year><volume>76</volume><fpage>11715</fpage><lpage>11720</lpage><pub-id pub-id-type="pmid">12388731</pub-id><pub-id pub-id-type="doi">10.1128/JVI.76.22.11715-11720.2002</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Williamson</surname><given-names>S</given-names></name></person-group><article-title>Adaptation in the env gene of HIV-1 and evolutionary theories of disease progression</article-title><source>Mol Biol Evol</source><year>2003</year><volume>20</volume><fpage>1318</fpage><lpage>1325</lpage><pub-id pub-id-type="pmid">12777505</pub-id><pub-id pub-id-type="doi">10.1093/molbev/msg144</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gilbert</surname><given-names>PB</given-names></name><name><surname>Peterson</surname><given-names>ML</given-names></name><name><surname>Follmann</surname><given-names>D</given-names></name><name><surname>Hudgens</surname><given-names>MG</given-names></name><name><surname>Francis</surname><given-names>DP</given-names></name><name><surname>Gurwith</surname><given-names>M</given-names></name><name><surname>Heyward</surname><given-names>WL</given-names></name><name><surname>Jobes</surname><given-names>DV</given-names></name><name><surname>Popovic</surname><given-names>V</given-names></name><name><surname>Self</surname><given-names>SG</given-names></name><etal></etal></person-group><article-title>Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial</article-title><source>J Infect Dis</source><year>2005</year><volume>191</volume><fpage>666</fpage><lpage>677</lpage><pub-id pub-id-type="pmid">15688279</pub-id><pub-id pub-id-type="doi">10.1086/428405</pub-id></citation></ref><ref id="B10"><citation citation-type="other"><person-group person-group-type="author"><name><surname>P&#x000e9;rez-Losada</surname><given-names>M</given-names></name><name><surname>Jobes</surname><given-names>DV</given-names></name><name><surname>Sinangil</surname><given-names>F</given-names></name><name><surname>Crandall</surname><given-names>KA</given-names></name><name><surname>Posada</surname><given-names>D</given-names></name><name><surname>Berman</surname><given-names>PW</given-names></name></person-group><article-title>Phylodynamics of gp120 sequences from a Phase 3 HIV-1 vaccine trial in North America</article-title><source>Mol Biol Evol</source><year>2009</year><comment>in review</comment></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Katoh</surname><given-names>K</given-names></name><name><surname>Kuma</surname><given-names>K</given-names></name><name><surname>Toh</surname><given-names>H</given-names></name><name><surname>Miyata</surname><given-names>T</given-names></name></person-group><article-title>MAFFT version 5: improvement in accuracy of multiple sequence alignment</article-title><source>Nucleic Acids Res</source><year>2005</year><volume>33</volume><fpage>511</fpage><lpage>518</lpage><pub-id pub-id-type="pmid">15661851</pub-id><pub-id pub-id-type="doi">10.1093/nar/gki198</pub-id></citation></ref><ref id="B12"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Korber</surname><given-names>B</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Rodrigo AG, Learn GH</surname></name></person-group><article-title>HIV signature and sequence variation analysis</article-title><source>Computational and evolutionary analysis of HIV molecular sequences</source><year>2000</year><volume>4</volume><publisher-name>Dordrecht, Netherlands: Kluwer Academic Publishers</publisher-name><fpage>55</fpage><lpage>72</lpage></citation></ref><ref id="B13"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Z</given-names></name></person-group><source>PAML: Phylogenetic Analysis by Maximum Likelihood</source><year>2001</year><edition>3.1</edition><publisher-name>London: University College London</publisher-name></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kosakovsky Pond</surname><given-names>SL</given-names></name><name><surname>Frost</surname><given-names>SDW</given-names></name><name><surname>Muse</surname><given-names>SV</given-names></name></person-group><article-title>HyPhy: hypothesis testing using phylogenies</article-title><source>Bioinformatics</source><year>2005</year><volume>21</volume><fpage>676</fpage><lpage>679</lpage><pub-id pub-id-type="pmid">15509596</pub-id><pub-id pub-id-type="doi">10.1093/bioinformatics/bti079</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kosakovsky Pond</surname><given-names>SL</given-names></name><name><surname>Posada</surname><given-names>D</given-names></name><name><surname>Gravenor</surname><given-names>MB</given-names></name><name><surname>Woelk</surname><given-names>CH</given-names></name><name><surname>Frost</surname><given-names>SD</given-names></name></person-group><article-title>GARD: a genetic algorithm for recombination detection</article-title><source>Bioinformatics</source><year>2006</year><volume>22</volume><fpage>3096</fpage><lpage>3098</lpage><pub-id pub-id-type="pmid">17110367</pub-id><pub-id pub-id-type="doi">10.1093/bioinformatics/btl474</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Benjamini</surname><given-names>Y</given-names></name><name><surname>Hochberg</surname><given-names>Y</given-names></name></person-group><article-title>Controlling the false discovery rate: a practical and powerful approach to multiple testing</article-title><source>J R Statist Soc B</source><year>1995</year><volume>57</volume><fpage>289</fpage><lpage>300</lpage></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sugimoto</surname><given-names>K</given-names></name><name><surname>Stadanlick</surname><given-names>J</given-names></name><name><surname>Ikeda</surname><given-names>F</given-names></name><name><surname>Brensinger</surname><given-names>C</given-names></name><name><surname>Furth</surname><given-names>EE</given-names></name><name><surname>Alter</surname><given-names>HJ</given-names></name><name><surname>Chang</surname><given-names>KM</given-names></name></person-group><article-title>Influence of ethnicity in the outcome of hepatitis C virus infection and cellular immune response</article-title><source>Hepatology</source><year>2003</year><volume>37</volume><fpage>590</fpage><lpage>599</lpage><pub-id pub-id-type="pmid">12601357</pub-id><pub-id pub-id-type="doi">10.1053/jhep.2003.50103</pub-id></citation></ref><ref id="B18"><citation citation-type="book"><person-group person-group-type="author"><collab>CDC</collab></person-group><source>HIV/AIDS Surveillance Report</source><year>2007</year><volume>19</volume><publisher-name>Atlanta: Centers for Disease Control and Prevention (CDC)</publisher-name></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Graham</surname><given-names>BS</given-names></name><name><surname>Mascola</surname><given-names>JR</given-names></name></person-group><article-title>Lessons from failure &#x02013; preparing for future HIV-1 vaccine efficacy trials</article-title><source>J Infect Dis</source><year>2005</year><volume>191</volume><fpage>647</fpage><lpage>649</lpage><pub-id pub-id-type="pmid">15688276</pub-id><pub-id pub-id-type="doi">10.1086/428406</pub-id></citation></ref></ref-list></back></article>


